Market Size of Pediatric Respiratory Disease Therapeutics Industry
Study Period | 2021 - 2029 |
Base Year For Estimation | 2023 |
CAGR | 5.60 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Pediatric Respiratory Disease Therapeutics Market Analysis
The pediatric respiratory disease therapeutics market is expected to register a CAGR of 5.6% over the forecast period.
The pandemic significantly impacted the pediatric respiratory disease therapeutics market as the demand for pediatric respiratory disease therapeutics products increased owing to the increased risk of respiratory illness. For instance, as per a study published by the NCBI in September 2022, low-field magnetic MRI showed persistent pulmonary dysfunction in both children and adolescents who recovered from COVID-19 and with long COVID. Similarly, per the study published by the IJP in November 2021, the pandemic has brought significant challenges to childcare worldwide. Respiratory disease therapeutics such as anti-inflammatory drugs, bronchodilators, and combination drugs are generally used for the treatment of various respiratory diseases. Thus, the increasing incidence of respiratory diseases among pediatrics and continuous treatment during the pandemic helped the market to maintain considerable growth. With the emergence of the new strain, the market is expected to move upward over the forecast period.
The increasing prevalence of chronic respiratory diseases and increasing research and development in drug discovery for respiratory diseases are the major drivers for the market. For instance, as per the report published by the WHO in October 2022, an estimated 10.6 million people suffered from tuberculosis (TB) in 2021 globally of which 1.2 million were children. The report also stated that TB is prevalent in all countries and age groups. In addition, the burden of asthma and allergic diseases continues to increase among pediatrics. Moreover, every year pediatric respiratory infections impose a significant burden on the global healthcare system in terms of manpower and resource utilization.
Furthermore, as per the October 2021 CDC report, there were more than 317 cases of tuberculosis disease among children aged 14 years or younger in the United States, accounting for 4.0% of all people reported with tuberculosis nationally in 2021. According to UNICEF data published in August 2022, there were more than 1,400 cases of pneumonia per 100,000 children, or 1 case in 71 children each year, globally, with the highest incidence occurring in South Asia (2,500 cases per 100,000 children) and West and Central Africa (1,620 cases per 100,000 children).
The increasing research and development in drug discovery is also another driving factor for the market. For instance, as per the journal published by the Frontiers Organization in October 2021, research is being conducted to identify prognostic respiratory disorder/disease progression-specific biomarkers that can predict disease course in children and to develop scoring and risk stratification systems. Similarly, in September 2021, Children's National Hospital received USD 2.13 million in awards from the National Institutes of Health's (NIH) National Heart, Lung and Blood Institute to accelerate research work and develop new diagnostic tools and innovative precision medicine related to treatments for kids with down syndrome experiencing respiratory viruses. It is expected that such advancements may create new opportunities for the market and may encourage new players to enter the market.
Pediatric Respiratory Disease Therapeutics Industry Segmentation
Pediatric respiratory disease therapeutics are specially approved medications to treat or alleviate respiratory diseases in pediatrics. Respiratory diseases are found to affect air passages, including nasal passages, bronchi, trachea, and lungs. Therefore they are also the major cause of mortality and morbidity in pediatrics. The Pediatric Respiratory Disease Therapeutics Market is segmented by Drug Class (Anti-Inflammatory Drugs, Bronchodilators, Combination Drugs, Corticosteroids, Monoclonal Antibodies, and Others), Disease (Asthma, Cystic Fibrosis, Bronchiolitis, Pneumonia, Tuberculosis, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (in USD million) for the above segments.
By Drug Class | |
Anti-Inflammatory Drugs | |
Bronchodilators | |
Combination Drugs | |
Corticosteroid | |
Monoclonal Antibodies | |
Other Drug Classes |
By Disease | |
Asthma | |
Cystic Fibrosis | |
Bronchiolitis | |
Pneumonia | |
Tuberculosis | |
Other Diseases |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Pediatric Respiratory Disease Therapeutics Market Size Summary
The pediatric respiratory disease therapeutics market is poised for significant growth, driven by the increasing prevalence of respiratory conditions among children and ongoing advancements in drug research and development. The market has experienced a surge in demand due to the heightened risk of respiratory illnesses during the pandemic, which underscored the importance of therapeutics such as anti-inflammatory drugs, bronchodilators, and combination therapies. The emergence of new strains continues to propel market expansion, as the need for effective treatments remains critical. Chronic respiratory diseases, including asthma and tuberculosis, are prevalent in pediatric populations, necessitating continuous innovation and development of targeted therapeutics. The market is further bolstered by research initiatives aimed at identifying biomarkers and developing precision medicine, which are expected to open new avenues for growth and attract new market entrants.
North America is anticipated to lead the pediatric respiratory disease therapeutics market, supported by a high incidence of respiratory conditions in children and a robust pipeline of research and product approvals. The region's market is characterized by a concentration of key players, strategic partnerships, and a strong focus on clinical trials and research activities. The competitive landscape is moderately fragmented, with major companies like Novartis AG, Bayer AG, and AstraZeneca plc playing pivotal roles. Recent product launches and regulatory approvals, such as AstraZeneca and Sanofi's Beyfortus for RSV prevention, highlight the dynamic nature of the market. These developments, coupled with the ongoing need for effective asthma treatments, are expected to drive sustained growth in the pediatric respiratory disease therapeutics sector.
Pediatric Respiratory Disease Therapeutics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Chronic Respiratory Diseases
-
1.2.2 Increasing Research and Development in Drug Discovery for Respiratory Diseases
-
-
1.3 Market Restraints
-
1.3.1 Stringent Regulations for Drug Approval
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
2.1 By Drug Class
-
2.1.1 Anti-Inflammatory Drugs
-
2.1.2 Bronchodilators
-
2.1.3 Combination Drugs
-
2.1.4 Corticosteroid
-
2.1.5 Monoclonal Antibodies
-
2.1.6 Other Drug Classes
-
-
2.2 By Disease
-
2.2.1 Asthma
-
2.2.2 Cystic Fibrosis
-
2.2.3 Bronchiolitis
-
2.2.4 Pneumonia
-
2.2.5 Tuberculosis
-
2.2.6 Other Diseases
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Pediatric Respiratory Disease Therapeutics Market Size FAQs
What is the current Pediatric Respiratory Disease Therapeutics Market size?
The Pediatric Respiratory Disease Therapeutics Market is projected to register a CAGR of 5.60% during the forecast period (2024-2029)
Who are the key players in Pediatric Respiratory Disease Therapeutics Market?
Regeneron Pharmaceuticals, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, F. Hoffmann-La Roche AG and Novartis AG are the major companies operating in the Pediatric Respiratory Disease Therapeutics Market.